Contineum Therapeutics Inc
NASDAQ:CTNM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Contineum Therapeutics Inc
Total Current Assets
Contineum Therapeutics Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Contineum Therapeutics Inc
NASDAQ:CTNM
|
Total Current Assets
$267.9m
|
CAGR 3-Years
77%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Total Current Assets
$18.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
7%
|
|
|
Schlumberger NV
NYSE:SLB
|
Total Current Assets
$19.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-3%
|
|
|
Halliburton Co
NYSE:HAL
|
Total Current Assets
$11.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-6%
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Total Current Assets
$1.9B
|
CAGR 3-Years
46%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Total Current Assets
$3.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
Contineum Therapeutics Inc
Glance View
Contineum Therapeutics Inc is a US-based company operating in industry. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2024-04-05. Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The firm is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).
See Also
What is Contineum Therapeutics Inc's Total Current Assets?
Total Current Assets
267.9m
USD
Based on the financial report for Dec 31, 2025, Contineum Therapeutics Inc's Total Current Assets amounts to 267.9m USD.
What is Contineum Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
77%
Over the last year, the Total Current Assets growth was 30%. The average annual Total Current Assets growth rates for Contineum Therapeutics Inc have been 77% over the past three years .
